Sedentary Behavior in Older Women With and Without Type 2 Diabetes

Description

Sedentary behavior has been linked to cardiovascular morbidity and mortality, and is particularly common in older adults with type 2 diabetes. The purpose of this observational, mixed-methods study is to better understand the relationship between prolonged sedentary behavior and cardiovascular and metabolic health in older women.

Conditions

Diabetes Mellitus, Type 2, Healthy

Talk to us

Study Overview

On this page

Study Details

Study overview

Sedentary behavior has been linked to cardiovascular morbidity and mortality, and is particularly common in older adults with type 2 diabetes. The purpose of this observational, mixed-methods study is to better understand the relationship between prolonged sedentary behavior and cardiovascular and metabolic health in older women.

Prolonged Sedentary Behavior in Older Women With and Without Type 2 Diabetes: Knowledge, Engagement, and Relationship to Cardiometabolic Risk

Sedentary Behavior in Older Women With and Without Type 2 Diabetes

Condition
Diabetes Mellitus, Type 2
Intervention / Treatment

-

Contacts and Locations

Aurora

University of Colorado Anschutz Medical Campus, Aurora, Colorado, United States, 80045

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Female
  • * Age 60-75 years
  • * Postmenopausal (self-reported)
  • * BMI between 25-40 kg/m2
  • * Participants with T2D:
  • * T2D confirmed via chart review
  • * T2D diet controlled or treated with the following acceptable medication treatments: metformin, sulfonylureas, glinides, or glucose absorption blockers
  • * Male
  • * Age \<60 or \>75 years
  • * Type 1 diabetes
  • * Control participants only - HbA1C ≥ 5.7%
  • * Use of beta blockers or centrally-acting calcium channel blockers (i.e., diltiazem, verapamil) due to potential blunting of cardiorespiratory fitness assessments
  • * Use of hormone replacement therapy (e.g., estrogen, progesterone, testosterone) (within the past 5 years)
  • * Taking insulin, thiazolidinediones (e.g., rosiglitazone), glucagon-like peptide-1 (GLP1) agonists (e.g., exenatide), dipeptidyl peptidase-4 (DPP4) inhibitors (e.g., sitagliptin) or any medication for the treatment of T2D other than those listed above in the inclusion criteria
  • * Uncontrolled hypertension at rest (systolic \>160 or diastolic \>110 mmHg)
  • * Obstructive pulmonary disease or asthma with a forced expiratory volume in 1 second (FEV1)/forced vital capacity (FVC) ratio \<70% of predicted
  • * Any of the following conditions:
  • * Uncontrolled T2D (HbA1C \>9.0%)
  • * Unstable angina
  • * Recent myocardial infarction, cardiac surgery, or vascular surgery (\<3 months)
  • * Heart failure
  • * Peripheral artery disease (based on report of symptomatic claudication or ankle brachial index testing)
  • * Anemia (tHb \<10 mg/dL)
  • * Hepatic or renal disease
  • * Severe arthritis or mobility impairment that would interfere with exercise testing
  • * Current tobacco or marijuana use or nicotine use within the last year
  • * Dementia or evidence of cognitive impairment (Mini-Cog score \< 3)
  • * Engaging in \>150 minutes/week of moderate to vigorous physical activity (assessed via Low-Level Physical Activity Recall questionnaire)

Ages Eligible for Study

60 Years to 75 Years

Sexes Eligible for Study

FEMALE

Accepts Healthy Volunteers

Yes

Collaborators and Investigators

University of Colorado, Denver,

Mary O Whipple, PhD, PRINCIPAL_INVESTIGATOR, University of Colorado, Denver

Study Record Dates

2024-10-11